This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Edwards Lifesciences (EW) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 14.89% and 4.93%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Bull of the Day: Penumbra (PEN)
by Kevin Cook
Until we have nano-bots to cruise our blood vessels, the catheter remains mightier than the scalpel
Flight Plan for Trading: Market Lessons from My Pilot Dad
by Kevin Cook
Learning to fly an airplane can build an excellent structured thought process for navigating markets.
Analysts Estimate Edwards Lifesciences (EW) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Edwards Lifesciences (EW) in Q1 Earnings?
by Zacks Equity Research
Continued strength in the adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve are likely to have driven Edwards Lifesciences' (EW) Q1 revenues.
Top Analyst Reports for Facebook, Adobe & Novo Nordisk
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Adobe (ADBE), and Novo Nordisk (NVO).
Bull of the Day: Penumbra (PEN)
by Kevin Cook
Leader in treating stroke with catheter-based technology has fully recovered from a product recall
Q4 Earnings Season Scorecard and Research Reports for Toyota, PepsiCo & BlackRock
by Sheraz Mian
We have provided a real-time update on the Q4 earnings season, in addition to featuring new research reports on 16 major stocks in today's Research Daily.
Edwards Lifesciences (EW) Q4 Earnings Fall Shy of Estimates
by Zacks Equity Research
Despite coronavirus-led business challenges, Edwards Lifesciences (EW) witnessed robust performances in TMTT business in Q4.
Edwards Lifesciences (EW) Q4 Earnings Lag Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of -5.66% and 0.71%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
5 Must-See Large Cap Earnings Charts
by Tracey Ryniec
While technology stocks remain hot in 2021, there are other sectors that should be on your radar this earnings season.
Top Analyst Reports for Walmart, Intel & Cisco
by Sheraz Mian
Today's Research Daily features new research reports on 12 major stocks, including Walmart (WMT), Intel (INTC), and Cisco Systems (CSCO).
What's in Store for Edwards Lifesciences in (EW) Q4 Earnings?
by Zacks Equity Research
Robust customer adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.
Bear of the Day: Penumbra (PEN)
by Kevin Cook
Revolutionary catheter-based treatment for stroke events encounters device problems and a recall
3 Best Buys from the Prospering Medical Instruments Industry
by Urmimala Biswas
Despite the challenges posed by the COVID-19 pandemic, higher demand for lab-testing products, digital influence, and AI and robotics is likely to lend support to the Zacks Medical - Instruments industry. TMO, IDXX and STE are well positioned to gain.
Edwards Lifesciences (EW) Beats on Q3 Earnings, Margins Up
by Zacks Equity Research
Despite coronavirus-led business challenges, Edwards Lifesciences (EW) witnessed steady improvement in TAVR procedure volumes in Q3.
Edwards Lifesciences (EW) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 13.33% and 5.52%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
5 Spectacular Earnings Charts
by Tracey Ryniec
These popular stocks have some of the best earnings charts of the week.
The Zacks Analyst Blog Highlights: Edwards Lifesciences, QIAGEN, IDEXX, LHC and ResMed
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Edwards Lifesciences, QIAGEN, IDEXX, LHC and ResMed
3 MedTech Growth Stocks to Scoop Up Ahead of Q3 Earnings
by Zacks Equity Research
Here are three growth stocks from the MedTech space that investors can pick ahead of the quarterly releases.
Earnings Preview: Edwards Lifesciences (EW) Q3 Earnings Expected to Decline
by Zacks Equity Research
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Edwards Lifesciences' (EW) Q3 Earnings?
by Zacks Equity Research
Robust customer adoption of the TruWave disposable pressure monitoring devices and the INSPIRIS RESILIA aortic valve is likely to have driven Edwards Lifesciences' (EW) Q3 revenues.
Edwards Lifesciences (EW) Up 1.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
TMO vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
TMO vs. EW: Which Stock Is the Better Value Option?
Edwards Lifesciences (EW) Beats on Q2 Earnings, Ups EPS View
by Zacks Equity Research
Despite coronavirus-hit sales, Edwards Lifesciences (EW) witnessed steady improvement in TAVR procedure volumes in Q2. Regulatory approvals look encouraging.